Solid Biosciences (SLDB) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
Annual meeting scheduled for June 10, 2026, at 8:00 AM ET, to be held virtually.
Shareholders are encouraged to review proxy materials and vote in advance or during the meeting.
Voting matters and shareholder proposals
Election of three Class II directors: Clare Kahn, Adam Stone, and Lynne Sullivan, with board recommendation to vote for all.
Advisory ratification of llan Ganot as a Class I Director until the 2028 annual meeting.
Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026.
Approval of an amendment to increase authorized common stock from 240,000,000 to 480,000,000 shares.
Advisory vote on executive compensation.
Board of directors and corporate governance
Board recommends all director nominees and advisory appointments.
Proxies are authorized to vote on other business as may arise during the meeting.
Latest events from Solid Biosciences
- Net loss rose to $54.8M in Q2 2026 as R&D spending increased; cash runway extends into mid-2028.SLDB
Q2 2026 - All proposals passed, including director elections and doubling authorized shares.SLDB
AGM 2026 - Gene therapy programs show robust efficacy, safety, and regulatory momentum for key indications.SLDB
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Duchenne and FA gene therapy programs show strong progress, with pivotal FDA meetings ahead.SLDB
Jefferies Global Healthcare Conference 2026 - Key clinical progress, $380.7M cash, and a $56.7M net loss with runway into 2028.SLDB
Q1 2026 - Stockholders will vote on director elections, auditor ratification, share increase, and executive pay.SLDB
Proxy filing - Gene therapy programs show strong safety, efficacy, and innovation, with key data readouts ahead.SLDB
25th Annual Needham Virtual Healthcare Conference - Virtual meeting to vote on directors, auditor, share increase, and executive pay; board supports all.SLDB
Proxy filing - Strong clinical progress and $240M financing extend cash runway into 2028 despite higher net loss.SLDB
Q4 2025